ArticleJournal of immunology research2026
Will It Be Possible in the Future to Target Innate Immunity Against Staphylococcus aureus Using Resident Microbiota and Plant Extracts?
Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Staphylococcus aureus remains a major cause of hospital- and community-acquired infections, successfully evading host defense mechanisms and escaping proposed vaccination strategies. The effective response of professional phagocytes is crucial in limiting the spread, tissue invasion, and subsequent infection by S. aureus. However, direct stimulation of innate immunity with S. aureus antigens is too risky due to their strong proinflammatory properties. Therefore, this study aimed to test the hypothesis that plant extracts trigger the gentle release of staphylococcal bioactive components that can modulate innate immunity. This strategy was tested in vitro; however, it may have future applications by employing the resident microbiota and dietary supplements containing plant extracts. In this study, the THP-1-derived macrophages were exposed to the supernatants of planktonic and biofilm S. aureus cultures pretreated with Viburnum opulus L. bark and fruit extracts. Vancomycin (VAN) and chlorogenic acid (ChA), used at subinhibitory concentrations, were included for comparison regarding the release of S. aureus active components. The cells were also exposed to purified bacterial cell wall components. Various elements of the immune response were assessed, including surface expression of cluster of differentiation (CD11c, CD206) via flow cytometry, cytokine production (tumor necrosis factor-alpha [TNF-α] and interleukin 10 [IL-10]) via ELISA, and S. aureus phagocytosis and intracellular killing using fluorescein isothiocyanate (FITC)-labeled bacteria and Alamar Blue staining. It was demonstrated that both supernatants from planktonic and biofilm S. aureus cultures pre-exposed to V. opulus extracts, as well as the bacterial cell wall components themselves, significantly increased TNF-α and IL-10 production by THP-1-derived macrophages and visibly reduced intracellular multiplication of engulfed S. aureus. The lack of changes in the surface CD marker expression may be a limitation of the model used (phorbol-12-myristate-13-acetate [PMA]-differentiated THP-1) rather than the phenomenon itself, that leads to a "ceiling effect". To sum up, the study presents V. opulus extracts as the triggers to release bioactive components from S. aureus cells, able to target innate immunity against staphylococci, which may be used in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.